Leading TCR space with bispecifics
Immunocore is leading the TCR therapeutics space with the first approved therapy, KIMMTRAK, in metastatic uveal melanoma, for which the 2022 launch in the US exceeded expectations. We believe that further market penetration in the community setting and in the EU could drive the company's stock in t
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.